ERBA Diagnostics (ERB) 10-Q10 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2014	Nov. 07, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'ERBA Diagnostics, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	44,008,221
Amendment Flag	'false	'
Entity Central Index Key	'0001095858	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS:	'	'
Cash and cash equivalents	$2,286,914	$4,031,071
Accounts receivable, net	6,385,317	5,546,715
Inventories, net	7,259,095	6,494,173
Related party receivables	1,898,407	1,834,732
Other current assets	833,371	395,196
Total current assets	18,663,104	18,301,887
PROPERTY, PLANT AND EQUIPMENT:	'	'
Land	352,957	352,957
Buildings and improvements	3,886,288	3,136,434
Machinery and equipment	3,464,866	3,831,213
Furniture and fixtures	2,027,512	2,216,720
	9,731,623	9,537,324
Less: accumulated depreciation	-7,953,216	-7,976,121
Property, plant and equipment, net	1,778,407	1,561,203
OTHER LONG-TERM ASSETS:	'	'
Intangible assets, net	1,241,210	1,480,151
Goodwill	3,494,619	3,494,619
Equipment on lease, net	588,601	586,785
Product license	183,909	226,349
Restricted deposits	435,227	204,686
Other assets	17,239	18,786
Total other long-term assets	5,960,805	6,011,376
Total assets	26,402,316	25,874,466
CURRENT LIABILITIES:	'	'
Accounts payable	1,843,111	1,953,906
Revolving line of credit	1,939,662	1,904,879
Other accrued expenses	2,383,385	2,894,430
Total current liabilities	6,166,158	6,753,215
OTHER LONG-TERM LIABILITIES:	'	'
Deferred tax liabilities	658,030	576,160
Other long-term liabilities	1,138,491	1,027,425
Total other long-term liabilities	1,796,521	1,603,585
Total liabilities	7,962,679	8,356,800
SHAREHOLDERSâ€™ EQUITY:	'	'
Common stock, par value $0.01, authorized 100,000,000 shares, issued and outstanding 44,008,221 in 2014 and 43,658,221 in 2013	440,082	436,582
Additional paid-in capital	53,439,773	53,081,370
Accumulated deficit	-35,117,399	-35,861,343
Accumulated other comprehensive loss	-322,819	-138,943
Total shareholdersâ€™ equity	18,439,637	17,517,666
Total liabilities and shareholdersâ€™ equity	$26,402,316	$25,874,466

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	44,008,221	43,658,221
Common stock, outstanding	44,008,221	43,658,221

Condensed_Consolidated_Stateme

Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
NET REVENUE	$6,469,488	$6,940,713	$20,381,257	$20,538,079
COST OF SALES	3,326,571	3,925,819	10,596,514	11,033,411
Gross profit	3,142,917	3,014,894	9,784,743	9,504,668
OPERATING EXPENSES:	'	'	'	'
Selling	931,259	1,327,460	3,192,135	4,009,650
General and administrative	1,750,267	1,403,495	4,752,106	4,331,719
Research and development	110,325	205,398	686,220	933,375
Total operating expenses	2,791,851	2,936,353	8,630,461	9,274,744
Income from operations	351,066	78,541	1,154,282	229,924
OTHER INCOME (EXPENSE), NET:	'	'	'	'
Interest expense	-17,105	-29,264	-96,195	-67,177
(Loss) gain on foreign currency transactions	-197,685	112,909	-211,890	138,164
Acquisition expenses	'	'	'	-211,045
Other income (expense), net	20,775	-5,663	-14,077	-40,368
Total other (expense) income, net	-194,015	77,982	-322,162	-180,426
Income before provision for income taxes	157,051	156,523	832,120	49,498
PROVISION FOR INCOME TAXES	-29,133	-27,294	-88,176	-79,988
Net income (loss)	127,918	129,229	743,944	-30,490
OTHER COMPREHENSIVE INCOME (LOSS):	'	'	'	'
Foreign currency translation adjustment	-302,889	420,765	-183,876	188,875
Total comprehensive income (loss)	($174,971)	$549,994	$560,068	$158,385
NET INCOME (LOSS) PER SHARE â€“ Basic (in Dollars per share)	$0	$0	$0.02	$0
NET INCOME (LOSS) PER SHARE â€“ Diluted (in Dollars per share)	$0	$0	$0.01	$0
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:	'	'	'	'
Basic (in Shares)	43,906,740	43,658,221	43,832,851	43,658,221
Diluted (in Shares)	55,236,760	46,937,852	54,650,237	43,658,221

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Shareholders' Equity (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balances as of December 31, 2013 at Dec. 31, 2013	$436,582	$53,081,370	($35,861,343)	($138,943)	$17,517,666
Balances as of December 31, 2013 (in Shares) at Dec. 31, 2013	43,658,221	'	'	'	'
Stock option exercises	3,500	307,000	'	'	310,500
Stock option exercises (in Shares)	350,000	'	'	'	350,000
Stock option grants	'	51,403	'	'	51,403
Net income	'	'	743,944	'	743,944
Foreign currency translation adjustment	'	'	'	-183,876	-183,876
Balances as of September 30, 2014 at Sep. 30, 2014	$440,082	$53,439,773	($35,117,399)	($322,819)	$18,439,637
Balances as of September 30, 2014 (in Shares) at Sep. 30, 2014	44,008,221	'	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income (loss)	$743,944	($30,490)
Adjustments to reconcile net income (loss) to net cash (used in) operating activities-	'	'
Depreciation and amortization	735,838	636,494
Provision (reduction) for doubtful accounts receivable	-151,573	107,917
Reversal of provision for inventory obsolescence	'	-6,011
Non-cash compensation	51,403	134,000
Deferred income tax provision	51,591	34,494
Changes in operating assets and liabilities:	'	'
Accounts receivable	-918,043	-800,695
Inventories	-881,246	-825,862
Other assets	-916,541	-728,968
Related party receivables	-215,875	'
Accounts payable and accrued expenses	-538,038	-308,488
Other long-term liabilities	366,917	-111,456
Net cash (used in) operating activities	-1,671,623	-1,899,065
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Capital expenditures	-218,967	-141,967
Acquisition of equipment on lease, net	-180,130	-122,266
Net cash (used in) investing activities	-399,097	-264,233
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Net proceeds from revolving line of credit	88,060	1,103,698
Proceeds from stock option exercises	310,500	'
Capital lease payments	'	-21,947
Net cash provided by financing activities	398,560	1,081,751
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	-71,997	225,745
NET CHANGE IN CASH AND CASH EQUIVALENTS	-1,744,157	-855,802
CASH AND CASH EQUIVALENTS, beginning of period	4,031,071	4,125,819
CASH AND CASH EQUIVALENTS, end of period	2,286,914	3,270,017
SUPPLEMENTAL DISCLOSURES:	'	'
Interest paid	$26,660	$67,177

Note_1_Organization_and_Operat

Note 1 - Organization and Operations	9 Months Ended
Note 1 - Organization and Operations	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	(1) ORGANIZATION AND OPERATIONS:

	General Information

	The accompanying unaudited interim condensed consolidated financial statements of ERBA Diagnostics, Inc. (the “Company,” “ERBA Diagnostics,” “we,” “us” or “our”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q and, therefore, do not include all information normally included in audited financial statements. However, in the opinion of management, all adjustments necessary to state fairly the results of operations, financial position, changes in stockholders’ equity and cash flows have been made. The results of operations, financial position, changes in stockholders’ equity and cash flows for the nine months ended September 30, 2014 are not necessarily indicative of the results of operations, financial position, changes in stockholders’ equity and cash flows which may be reported for the remainder of 2014. The consolidated balance sheet as of December 31, 2013 was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

	The Company is a Delaware corporation and, through its subsidiaries, is engaged in developing, manufacturing and marketing diagnostic test kits, reagents and instruments for use in hospitals, reference laboratories, clinical laboratories, research laboratories, doctors' offices and other commercial companies. The Company’s products and instrumentation are sold to customers globally.

	On September 1, 2010, ERBA Diagnostics Mannheim GmbH, an in vitro diagnostics company headquartered in Germany (“ERBA Mannheim”), the parent company of which is Transasia Bio-Medicals Ltd. (“Transasia”), purchased all of the approximately 72.4% of the outstanding shares of the Company’s common stock then owned by the Debregeas-Kennedy Group for an aggregate purchase price of approximately $15,000,000, or $0.75 per share. As a result of this share acquisition, the consummation of the various transactions contemplated by the investment made by ERBA Mannheim pursuant to that certain Stock Purchase Agreement, as further described below, including ERBA Mannheim’s purchase from the Company, and the Company’s issuance to ERBA Mannheim, of an aggregate of 15,333,334 shares of the Company’s common stock, and ERBA Mannheim’s exercise, in part, of the Warrant, as further described below, for 600,000 shares of the Company’s common stock, ERBA Mannheim now beneficially owns, directly or indirectly, approximately 82% of the outstanding shares of the Company’s common stock.

Note_2_Liquidity

Note 2 - Liquidity	9 Months Ended
Note 2 - Liquidity	Sep. 30, 2014
Liquidity Disclosures [Abstract]	'
Liquidity Disclosures [Text Block]	'
	(2) LIQUIDITY:

	The Company achieved a net income of approximately $744,000 during the nine months ended September 30, 2014 and incurred a net loss of approximately $30,000 during the nine months ended September 30, 2013 and had cash used in operations of approximately $1,672,000 and approximately $1,899,000 for those respective periods.

	As discussed in Note 13, Revolving Line of Credit, on January 1, 2014, Diamedix Corporation (“Diamedix”), a wholly-owned subsidiary of the Company, extended the term of its loan agreement with Citibank, N.A., which provides for a secured, revolving credit facility of up to $2,000,000, for an additional year, thereby making the maturity date December 31, 2014. The Company expects to renew the line of credit upon its maturity.

Note_3_StockBased_Compensation

Note 3 - Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	(3) STOCK-BASED COMPENSATION:

	Valuations are based upon highly subjective assumptions about the future, including stock price volatility and exercise patterns. The fair value of share-based payment awards was estimated using the Black-Scholes option pricing model. Expected volatilities are based on the historical volatility of the Company’s stock. The Company uses historical data to estimate option exercise and employee terminations. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.

	The Company has historically granted options under the Company’s option plans with an option exercise price equal to the closing market value of the stock on the date of the grant and with vesting, primarily for Company employees, ranging from all at once to equal annual amounts over a four year period, and, primarily for non-employee directors, immediately.

	During the nine months ended September 30, 2014, a member of the Company’s Board of Directors and a former executive officer of the Company exercised 350,000 stock options at a weighted average exercise price of $0.89 for total cash proceeds of approximately $310,000.

	On May 22, 2014, the Company granted to its independent directors stock options to purchase an aggregate of 30,000 shares of the Company’s common stock at an exercise price of $1.76 per share. The options vested immediately and expire on May 21, 2024. The fair market value of such stock option was $1.76 per stock option based on the Black-Scholes valuation model.

	On June 1, 2014, the Company granted to an executive officer stock options to purchase 25,000 shares of the Company’s common stock at an exercise price of $1.76 per share. The options have a one year vesting period and expire on May 31, 2024. The fair market value of such stock option was $1.76 per stock option based on the Black-Scholes valuation model.

	On June 6, 2014, the Company granted to an executive officer stock options to purchase 10,000 shares of the Company’s common stock at an exercise price of $1.63 per share. The options have a three year vesting period and expire on May 31, 2024. The fair market value of such stock option was $1.63 per stock option based on the Black-Scholes valuation model.

	There was stock-based compensation expense of approximately $4,000 and $51,000 for the three and nine months ended September 30, 2014, respectively, and stock-based compensation expense of $134,000 for both the three and nine months ended September 30, 2013.

	The following table summarizes the stock option activity for the nine months ended September 30, 2014:

		Number of			Weighted Average
		Shares			Exercise Price
	Balance as of December 31, 2013		1,170,870		$	1.33
	Stock options granted		65,000		$	1.77
	Stock options exercised		(350,000	)	$	0.89
	Balance as of September 30, 2014		885,870		$	1.54

Note_4_Cash_and_Cash_Equivalen

Note 4 - Cash and Cash Equivalents	9 Months Ended
Note 4 - Cash and Cash Equivalents	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents Disclosure [Text Block]	'
	(4) CASH AND CASH EQUIVALENTS:

	The Company considers certain short-term investments in money market accounts with original maturities of three months or less to be cash equivalents.

Note_5_Accounts_Receivable_and

Note 5 - Accounts Receivable and Allowance for Doubtful Accounts	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	'
	(5) ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS:

	The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained, particularly in Italy where payment cycles are longer than in the United States and in some instances may take in excess of a year to collect, for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been followed in accordance with the Company’s policies. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.

	The Company periodically receives payments based upon negotiated agreements with governmental regions in Italy, acting on behalf of hospitals located in the region, in satisfaction of previously outstanding accounts receivable balances. The Company may have anticipated collection of these amounts through a payment as described above and, therefore, not provided an allowance for doubtful accounts for these amounts. Future payments by governmental regions in Italy are possible and, as a result, the Company may consider the potential receipt of those payments in determining its allowance for doubtful accounts. If contemplated payments are not received when expected or at all, or if negotiated agreements are not complied with in a timely manner or cancelled, then the Company may provide additional allowances for doubtful accounts.

	Accounts receivable, net, consists of the following:

		September 30,			December 31,
		2014			2013
	Accounts receivable	$	7,515,114		$	6,964,357
	Less: allowance for doubtful accounts		(1,129,797	)		(1,417,642	)
	Accounts receivable, net	$	6,385,317		$	5,546,715

Note_6_Inventories_Net

Note 6 - Inventories, Net	9 Months Ended
Note 6 - Inventories, Net	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	(6) INVENTORIES, NET:

	Inventories, net consist of the following:

		September 30,		December 31,
		2014		2013

	Raw materials	$	1,068,047	$	3,123,380
	Work-in-process		748,664		624,454
	Finished goods		5,442,384		2,746,339
	Total inventories, net	$	7,259,095	$	6,494,173

Note_7_Income_Loss_Per_Share

Note 7 - Income (Loss) Per Share	9 Months Ended
Note 7 - Income (Loss) Per Share	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	(7) INCOME (LOSS) PER SHARE:

	Basic income (loss) per share excludes any dilution. It is based upon the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock. A total of 150,000 share based awards were excluded from the calculation of diluted earnings per shares for the three and nine months ended September 30, 2014 and a total of 12,674,573 and 15,854,204 share based awards were excluded from the calculation of diluted earnings per share for three and nine months ended September 30, 2013, respectively, as they were anti-dilutive.

Note_8_Income_Taxes

Note 8 - Income Taxes	9 Months Ended
Note 8 - Income Taxes	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	(8) INCOME TAXES:

	The (provision) for/benefit from income taxes consists of the following for the three and nine months ended September 30, 2014 and 2013:

		Three Months						Nine months
		2014			2013			2014			2013
	Current:
	Foreign	$	(11,936	)	$	(10,017	)	$	(36,585	)	$	(33,688	)

	Deferred:
	Domestic		(17,197	)		(17,277	)		(51,591	)		(46,300	)
	Total	$	(29,133	)	$	(27,294	)	$	(88,176	)	$	(79,988	)

	The Company is susceptible to large fluctuations in its effective tax rate and has thereby recognized income tax expense on a discrete pro-rata basis for the nine month periods ended September 30, 2014 and 2013. In addition, no current domestic income tax provision was recorded during the same periods, due to utilization of valuation allowance to offset domestic income of approximately $709,000 during the nine month period ended September 30, 2014 and $291,000 during the nine month period ended September 30, 2013. The foreign current income tax provisions for the three and nine months ended September 30, 2014 and 2013 were primarily the result of Italian local income taxes based upon applicable statutory rates effective in Italy.

	The Company has established a full valuation allowance on its net domestic deferred tax assets, which are primarily comprised of net operating loss carryforwards. Accordingly, as of September 30, 2014 and December 31, 2013, the Company had no net domestic deferred tax assets. As of September 30, 2014 and December 31, 2013, the Company had net deferred tax liabilities of $658,030 and $576,160, respectively, relating to tax deductible goodwill which is not expected to reverse in the foreseeable future. Additionally, as of September 30, 2014 and December 31, 2013, the Company also had no net foreign deferred tax asset, as a full valuation allowance was provided. Future changes in the estimated net realizable value of the deferred tax assets or deferred tax liabilities could cause the provision for income taxes to vary significantly from period to period.

	Domestic net operating losses generated by the Company total approximately $18,110,000 as of December 31, 2013 and are subject to any applicable limitations as described below. The net operating losses included in the domestic net deferred tax asset will begin to expire in 2023. Under Section 382 of the Internal Revenue Code, the Company’s use of its net operating loss carryforwards will be limited in the future as a result of the September 1, 2010 acquisition by ERBA Mannheim of the approximately 72.4% of the then outstanding shares of the Company’s common stock previously owned by the Debregeas-Kennedy Group. As a result of that acquisition, the Company’s ability to utilize net operating loss carryforwards to offset any future taxable income is currently limited to approximately $827,000 per year, plus both any limitation unused since the acquisition and any unused net operating losses generated after the September 1, 2010 acquisition date. The amount of the annual limitation will be adjusted upwards for any recognized built-in gains on certain assets sold during the five year period commencing with the ownership change. The limitations of these net operating loss carryforwards did not impact the Company’s results for the nine months ended September 30, 2014 and 2013.

	United States income taxes have not been provided on undistributed earnings of foreign subsidiaries, as such earnings are being retained indefinitely by such subsidiaries for reinvestment. The distribution of these earnings would first reduce the domestic valuation allowance before resulting in additional United States income taxes.

	For the nine month period ended September 30, 2014 and 2013, we have recorded income tax provisions of approximately $88,000 and $80,000, respectively. The current portion of our tax provisions in both years relates to Italian local income taxes based upon applicable statutory rates effective in Italy. In addition, the domestic provision of approximately $52,000 for 2014 and $46,000 for 2013 represent the deferred tax provisions in these years relating to domestic tax-deductible goodwill. No current tax benefit was recorded during the two years on our losses because we had a full valuation allowance against the net deferred income tax assets.

	In prior years, we have experienced net losses from our operations. In accordance with GAAP, we are required to record a valuation allowance against the deferred tax asset associated with these losses if it is “more likely than not” that we will not be able to utilize the net operating loss to offset future taxes. Due to the cumulative net losses from the operations of both our domestic and European operations, we have provided a full valuation allowance against our deferred tax assets as of September 30, 2014. Over time we may reach levels of profitability that could cause our management to conclude that it is more likely than not that we will realize all or a portion of our net operating loss carryforwards and other temporary differences. Upon reaching such a conclusion, and upon such time as we reverse the entire amount or a portion of the valuation allowance against the deferred tax asset, we would then provide for income taxes at a rate equal to our effective tax rate.

Note_9_Concentration_of_Credit

Note 9 - Concentration of Credit Risk	9 Months Ended
Note 9 - Concentration of Credit Risk	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	(9) CONCENTRATION OF CREDIT RISK:

	The Company performs periodic credit evaluations of its customers’ financial condition and provides allowances for doubtful accounts as required. The Company maintains allowances for doubtful accounts, particularly in Italy where payment cycles are longer than in the United States, for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Additionally, the Company periodically receives payments based upon negotiated agreements with governmental regions in Italy, acting on behalf of hospitals located in the region, in satisfaction of previously outstanding accounts receivable balances.

	A substantial portion of the Company’s accounts receivable and revenues are derived from Delta Biologicals, S.r.l., the Company’s subsidiary located in Italy (“Delta Biologicals”), and its operations may be affected by the recent fiscal and debt crisis the Italian government is facing. As of September 30, 2014 and December 31, 2013, Delta Biologicals’ gross accounts receivable, primarily due from Italian companies, were approximately $4,007,000 and $4,647,000, respectively. Amounts due from hospitals and laboratories controlled by the Italian government as of September 30, 2014 and December 31, 2013 were approximately $1,306,000 and $1,700,000, respectively, which accounted for approximately 20% and 31%, respectively, of the Company’s consolidated net accounts receivable. Delta Biologicals recognized revenues during the nine month ended September 30, 2014 and 2013 of approximately $4,292,000 and $3,505,000, respectively, which represented approximately 21% and 17%, respectively, of the Company’s consolidated net revenues.

	In recent years, the Italian government has been experiencing severe fiscal and debt crises and a recession, including its increasingly uncertain ability to service its sovereign debt obligations, caused in part by the declining global markets and economic conditions. Accordingly, the Company is subject to certain economic, business and, in particular, credit risk if its customers located in Italy, which are hospitals or laboratories controlled by the Italian government, do not pay amounts owed to the Company, extend payment cycles even further or ask the Company to accept a lower payment amount than is owed to the Company. The Company’s current allowances for doubtful accounts, although currently believed by management to be adequate, may not be adequate and the Company may be required to make additional allowances, which would adversely affect, and could materially adversely affect, the Company’s operating results in the period in which the determination or allowance is or was made. Any of these factors could materially and adversely affect the Company’s business, prospects, operating results, financial condition and cash flows in the near term.

	The Company’s cash management and investment policies restrict investments to low-risk, highly liquid securities, and the Company performs periodic evaluations of the credit standing of the financial institutions with which it deals. A significant portion of the Company’s cash and cash equivalents are presently held at one international securities brokerage firm. Accordingly, the Company is subject to credit risk if this brokerage firm is unable to repay the balance in the account or deliver the Company’s securities or if the brokerage firm should become bankrupt or otherwise insolvent. From time to time, the Company’s cash balances exceed federally insured limits.

Note_10_Segment_Information

Note 10 - Segment Information	9 Months Ended
Note 10 - Segment Information	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	(10) SEGMENT INFORMATION:

	The Company’s management reviews financial information, allocates resources and manages its business by geographic region. The domestic region, which includes corporate expenditures, contains the Company’s subsidiaries in the United States. The European region contains Delta Biologicals. The information provided is based on internal reports and was developed and utilized by management to track trends and changes in the results of the regions. The information, including the allocations of expense and overhead, was calculated based on a management approach and may not reflect the actual economic costs, contributions or results of operations of the regions as stand-alone businesses. If a different basis of presentation or allocation were utilized, the relative contributions of the regions might differ but the relative trends would, in management's view, likely not be materially impacted. The table below sets forth net revenues, income (loss) from operations, total assets and goodwill by region for the three and nine months ended September 30, 2014 and 2013:

	Three Months Ended	Domestic		European			Eliminations			Total

	September 30, 2014:
	External net sales	$	5,231,530	$	1,237,958		$	-		$	6,469,488
	Intercompany sales		80,433		8,721			(89,154	)		-
	Net revenue	$	5,311,963	$	1,246,679		$	(89,154	)	$	6,469,488

	Income (loss) from operations	$	375,555	$	(24,489	)	$	-		$	351,066

	September 30, 2013:
	External net sales	$	5,711,672	$	1,229,041		$	-		$	6,940,713
	Intercompany sales		60,167		3,075			(63,242	)		-
	Net revenue	$	5,771,839	$	1,232,116		$	(63,242	)	$	6,940,713

	Income (loss) from operations	$	219,149	$	(140,608	)	$	-		$	78,541

	Nine Months Ended	Domestic		European			Eliminations			Total

	September 30, 2014:
	External net sales	$	16,114,540	$	4,266,717		$	-		$	20,381,257
	Intercompany sales		290,559		25,054			( 315,613	)		-
	Net revenue	$	16,405,099	$	4,291,771		$	( 315,613	)	$	20,381,257

	Income from operations	$	1,008,084	$	146,198		$	-		$	1,154,282

	Assets	$	41,177,570	$	5,684,971		$	( 20,460,225	)	$	26,402,316
	Goodwill	$	3,494,619	$	-		$	-		$	3,494,619

	September 30, 2013:
	External net sales	$	17,049,329	$	3,488,750		$	-		$	20,538,079
	Intercompany sales		296,457		16,529			(312,986	)		-
	Net revenue	$	17,345,786	$	3,505,279		$	(312,986	)	$	20,538,079

	Income (loss) from operations	$	721,528	$	(491,604	)	$	-		$	229,924

	Assets	$	40,493,671	$	5,610,765		$	(20,460,225	)	$	25,644,211
	Goodwill	$	3,494,619	$	-		$	-		$	3,494,619

Note_11_Commitments_and_Contin

Note 11 - Commitments and Contingencies	9 Months Ended
Note 11 - Commitments and Contingencies	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	(11) COMMITMENTS AND CONTINGENCIES:

	The Company is involved in various legal claims and actions and regulatory matters, and other notices and demand proceedings arising in the ordinary course of business. While it is not possible to predict or determine the outcome of these proceedings, in the opinion of management, based on a review with legal counsel, any losses resulting from such legal proceedings would not have a material adverse impact on the financial position, results of operations or cash flows of the Company.

Note_12_Related_Party_Transact

Note 12 - Related Party Transactions	9 Months Ended
Note 12 - Related Party Transactions	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	(12) RELATED PARTY TRANSACTIONS:

	Certain Relationships and Related Transactions

	The Company sold products to Transasia, and a subsidiary of ERBA Mannheim, in the amount of approximately $1,280,000 and $1,874,000, for the three and nine months ended September 30, 2014, respectively, and approximately $24,000 and $70,000 for the three and nine months ended September 30, 2013, respectively.

	During 2011, Delta Biologicals entered into a contract research and development agreement with ERBA Mannheim, as amended, for a total of Euro 754,700, pursuant to which ERBA Mannheim agreed to pay the subsidiary a total amount of Euro 133,000 (equivalent to approximately $186,000) during the fourth quarter of 2011 and an additional Euro 621,700 (equivalent to approximately $799,000) during the year ended December 31, 2012 for the results of certain research and development. Further research and development has occurred subsequent to 2012 under the agreement. For the three and nine months ended September 30, 2014, the Company recognized research and development revenue under this agreement in the amount of approximately Euro 148,000 (equivalent to approximately $200,000) and approximately Euro 286,000 (equivalent to approximately $387,000), respectively.

	The Company had total net accounts receivable from ERBA Mannheim and Transasia of approximately $1,898,000 and $1,835,000 as of September 30, 2014 and December 31, 2013, respectively, related to the above transactions and receivables from the sale of products and the reimbursement of various expenditures incurred on behalf of ERBA Mannheim.

	On June 15, 2012, the Company entered into a use of name license agreement with ERBA Mannheim granting a royalty-free, non-exclusive license to use the name “ERBA” for an annual fee of one dollar. The license agreement will be terminated upon the earlier of (a) the transfer by ERBA Mannheim to the Company of all of ERBA Mannheim’s rights, title and interest in and to the use of the name and any stylized logos or marks associated with the name (the date that such transfer becomes effective, the “Transfer Date”) and (b) such time, if any, as ERBA Mannheim no longer owns, directly or indirectly, shares of the Company’s common stock representing more than 50% of the issued and outstanding shares of such stock (the “Share Threshold Date”). Furthermore, ERBA Mannheim may terminate the license agreement at any time prior to the earlier of the Transfer Date and the Share Threshold Date: (a) upon providing the Company 180 days prior written notice of its intent to terminate and the date upon which the license agreement shall terminate; or (b) upon providing the Company 30 days prior written notice of any breach of the license agreement by the Company, which breach remains uncured at the end of such 30 day period.

	In December 2012, JAS Diagnostics entered into a Research and Development Outsourcing Agreement with ERBA Diagnostics France SARL (“ERBA Diagnostics France”), pursuant to which JAS Diagnostics has agreed to pay ERBA Diagnostics France a total amount of Euro 350,000 (equivalent to approximately $462,500) plus additional material costs, in seven monthly installments of Euro 50,000 from December 2012 through June 2013, for certain research and development endeavors.

	On July 24, 2013, JAS Diagnostics and ERBA Diagnostics France mutually terminated the agreement above and ERBA Diagnostics France refunded to JAS Diagnostics all amounts paid under the agreement as of December 31, 2013.

	Common Stock and Equity Transactions

	The Company entered into the Stock Purchase Agreement with ERBA Mannheim, on April 8, 2011, pursuant to which the Company agreed to sell and issue to ERBA Mannheim an aggregate of 20,000,000 shares of the Company’s common stock for an aggregate purchase price of $15,000,000, or $0.75 per share of the Company’s common stock, and warrants to purchase an additional 20,000,000 shares of the Company’s common stock. The consummation of the investment contemplated by the Stock Purchase Agreement was subject to, among other things, the approval of holders of at least 66.66% of the issued and outstanding shares of the Company’s common stock (excluding any shares beneficially owned, directly or indirectly, by ERBA Mannheim). At the 2011 Annual Meeting of Stockholders held on June 10, 2011, the required approval of the Company’s stockholders was achieved.

	On June 30, 2011, ERBA Mannheim paid the Company $5,000,000 in order to consummate the initial transactions contemplated by the Stock Purchase Agreement (the “Initial Closing”). As a result, at the Initial Closing, the Company issued to ERBA Mannheim 6,666,667 shares of common stock and, in connection with the consummation of the initial transactions contemplated by the Stock Purchase Agreement, a warrant to purchase an additional 20,000,000 shares of common stock (the “Warrant”). After giving effect to transaction costs of $399,700 relating to the Stock Purchase Agreement, the Company received net proceeds of $4,600,300 at the consummation of the initial transactions contemplated by the Stock Purchase Agreement. The Warrant has a five year term and an exercise price per share of the Company’s common stock of $0.75 and is exercisable only to the extent that shares of the Company’s common stock have been purchased under the Stock Purchase Agreement.

	On April 16, 2012, ERBA Mannheim exercised, in part, the Warrant by paying an aggregate exercise price of $450,000 and, in connection therewith, the Company issued to ERBA Mannheim 600,000 shares of the Company’s common stock. A total of 19,400,000 warrants remain unexercised as of September 30, 2014 and 2013. As of September 30, 2014 and 2013, the Warrant was exercisable for 14,733,334 shares of the Company’s common stock.

	Pursuant to amendments to the Stock Purchase Agreement on December 29, 2011 and October 3, 2012, each of which was unanimously approved by the independent directors on the Board of Directors, the Company and ERBA Mannheim agreed that the Company would sell and issue to ERBA Mannheim, and ERBA Mannheim would purchase from the Company, 8,666,667 shares of common stock at the second closing of the transactions contemplated by the Stock Purchase Agreement (the “Second Closing”) for an aggregate purchase price of $6,500,000, or $0.75 per share, and 4,666,666 shares of common stock at the final closing of the transactions contemplated by the Stock Purchase Agreement (the “Final Closing”) for an aggregate purchase price of $3,500,000, or $0.75 per share. In addition, pursuant to the amendments to the Stock Purchase Agreement, the Company and ERBA Mannheim agreed to hold the Second Closing as promptly as practicable on or after October 3, 2012 and to hold the Final Closing on the date that is 60 days after the date on which a majority of the independent directors on the Board of Directors determines by vote or written consent that such issuance, sale and purchase shall occur and causes notice thereof to be delivered to ERBA Mannheim.

	The Second Closing was held on October 3, 2012, at which time ERBA Mannheim paid the $6,500,000 aggregate purchase price to the Company, and, in connection therewith, the Company issued to ERBA Mannheim 8,666,667 shares of the Company’s common stock. The Company used all of the proceeds of the Second Closing to consummate the October 3, 2012 acquisition of Drew Scientific.

	Other Transactions

	During the nine months ended September 30, 2013, ImmunoVision paid $6,000 to John B. Harley, M.D., Ph.D., a member of the Company’s Board of Directors, under that certain oral consulting agreement between Dr. Harley and ImmunoVision pursuant to which Dr. Harley was paid $2,000 per month in consideration for his provision of technical guidance and business assistance to the subsidiary on an as-needed basis. The oral consulting agreement ended in May 2013.

	Pursuant to a license agreement between the Company and Dr. Harley, he has granted an exclusive worldwide license to the Company for certain patents, rights and technology relating to monoclonal antibodies against autoimmune RNA proteins developed by him in exchange for specified royalty payments, including an annual minimum royalty of $10,000 for each licensed product utilized by the Company. For the three and nine months ended September 30, 2014 , the Company has expensed the minimum $2,500 under such agreement. For the three and nine months ended September 30, 2013, the Company expensed $0 and $5,000, respectively.

	The amounts paid to Dr. Harley were in addition to the amounts he received for his service as member of the Company’s Board of Directors and the committees of the Board of Directors on which he served. At the Company’s 2014 Annual Meeting of Stockholders held on May 20, 2014, Dr. Harley did not stand for re-election to the Board of Directors. Accordingly, Dr. Harley’s term of service as a director expired at the Company’s 2014 Annual Meeting of Stockholders.

Note_13_Revolving_Line_of_Cred

Note 13 - Revolving Line of Credit	9 Months Ended
Note 13 - Revolving Line of Credit	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	(13) REVOLVING LINE OF CREDIT:

	On March 1, 2013, the Company entered into that certain Business Loan Agreement and that certain Promissory Note with Citibank, N.A. (“Citibank”), which provides for a secured, revolving credit facility of up to $2,000,000 (the “Line of Credit”). Amounts outstanding under the Line of Credit will accrue interest at an annual rate equal to the 30-day LIBOR plus 1.75% (1.9% at September 30, 2014) and, as a result of the amendment entered into on January 1, 2014, will become due and payable on December 31, 2014, subject to acceleration upon the occurrence of certain specified events of default that the Company believes are customary for transactions of this type. Pursuant to the business loan agreement, the Company will be subject to certain specified positive and negative covenants (including, without limitation, the requirements to maintain a specified capital base of not less than $8,500,000 and a specified leverage ratio, as defined, of not less than 2.0-to-1.0) that the Company believes are customary for transactions of this type.

	Amounts outstanding under the Line of Credit have been collateralized by all of the assets of the Company and its wholly-owned subsidiaries located in the United States — Diamedix, ImmunoVision, and Drew Scientific. In addition, each of Diamedix, ImmunoVision and Drew Scientific has guaranteed the repayment of amounts drawn on the Line of Credit. Further, Transasia, the indirect parent company of the Company, has also guaranteed the repayment of amounts drawn on the Line of Credit.

	As of September 30, 2014 and December 31, 2013, approximately $1,940,000 and 1,905,000, respectively, was outstanding under the Line of Credit.

Note_3_StockBased_Compensation1

Note 3 - Stock-Based Compensation (Tables)	9 Months Ended
Note 3 - Stock-Based Compensation (Tables)	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Number of			Weighted Average
		Shares			Exercise Price
	Balance as of December 31, 2013		1,170,870		$	1.33
	Stock options granted		65,000		$	1.77
	Stock options exercised		(350,000	)	$	0.89
	Balance as of September 30, 2014		885,870		$	1.54

Note_5_Accounts_Receivable_and1

Note 5 - Accounts Receivable and Allowance for Doubtful Accounts (Tables)	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
Allowance For Doubtful Accounts [Table Text Block]	'
		September 30,			December 31,
		2014			2013
	Accounts receivable	$	7,515,114		$	6,964,357
	Less: allowance for doubtful accounts		(1,129,797	)		(1,417,642	)
	Accounts receivable, net	$	6,385,317		$	5,546,715

Note_6_Inventories_Net_Tables

Note 6 - Inventories, Net (Tables)	9 Months Ended
Note 6 - Inventories, Net (Tables)	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		September 30,		December 31,
		2014		2013

	Raw materials	$	1,068,047	$	3,123,380
	Work-in-process		748,664		624,454
	Finished goods		5,442,384		2,746,339
	Total inventories, net	$	7,259,095	$	6,494,173

Note_8_Income_Taxes_Tables

Note 8 - Income Taxes (Tables)	9 Months Ended
Note 8 - Income Taxes (Tables)	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		Three Months						Nine months
		2014			2013			2014			2013
	Current:
	Foreign	$	(11,936	)	$	(10,017	)	$	(36,585	)	$	(33,688	)

	Deferred:
	Domestic		(17,197	)		(17,277	)		(51,591	)		(46,300	)
	Total	$	(29,133	)	$	(27,294	)	$	(88,176	)	$	(79,988	)

Note_10_Segment_Information_Ta

Note 10 - Segment Information (Tables)	9 Months Ended
Note 10 - Segment Information (Tables)	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Three Months Ended	Domestic		European			Eliminations			Total

	September 30, 2014:
	External net sales	$	5,231,530	$	1,237,958		$	-		$	6,469,488
	Intercompany sales		80,433		8,721			(89,154	)		-
	Net revenue	$	5,311,963	$	1,246,679		$	(89,154	)	$	6,469,488

	Income (loss) from operations	$	375,555	$	(24,489	)	$	-		$	351,066

	September 30, 2013:
	External net sales	$	5,711,672	$	1,229,041		$	-		$	6,940,713
	Intercompany sales		60,167		3,075			(63,242	)		-
	Net revenue	$	5,771,839	$	1,232,116		$	(63,242	)	$	6,940,713

	Income (loss) from operations	$	219,149	$	(140,608	)	$	-		$	78,541
	Nine Months Ended	Domestic		European			Eliminations			Total

	September 30, 2014:
	External net sales	$	16,114,540	$	4,266,717		$	-		$	20,381,257
	Intercompany sales		290,559		25,054			( 315,613	)		-
	Net revenue	$	16,405,099	$	4,291,771		$	( 315,613	)	$	20,381,257

	Income from operations	$	1,008,084	$	146,198		$	-		$	1,154,282

	Assets	$	41,177,570	$	5,684,971		$	( 20,460,225	)	$	26,402,316
	Goodwill	$	3,494,619	$	-		$	-		$	3,494,619

	September 30, 2013:
	External net sales	$	17,049,329	$	3,488,750		$	-		$	20,538,079
	Intercompany sales		296,457		16,529			(312,986	)		-
	Net revenue	$	17,345,786	$	3,505,279		$	(312,986	)	$	20,538,079

	Income (loss) from operations	$	721,528	$	(491,604	)	$	-		$	229,924

	Assets	$	40,493,671	$	5,610,765		$	(20,460,225	)	$	25,644,211
	Goodwill	$	3,494,619	$	-		$	-		$	3,494,619

Note_1_Organization_and_Operat1

Note 1 - Organization and Operations (Details) (USD $)	1 Months Ended
Note 1 - Organization and Operations (Details) (USD $)	Sep. 30, 2010	Sep. 01, 2010
Note 1 - Organization and Operations (Details) [Line Items]	'	'
Business Acquisition, Percentage of Voting Interests Acquired	'	72.40%
Stock Purchase Agreement [Member] \| Diagnostics Mannheim GmbH [Member]	'	'
Note 1 - Organization and Operations (Details) [Line Items]	'	'
Business Acquisition, Percentage of Voting Interests Acquired	82.00%	72.40%
Equity Method Investment, Aggregate Cost	'	$15,000,000
Business Acquisition, Share Price	'	$0.75
Stock Issued During Period, Shares, New Issues	15,333,334	'
Stock Shares Issued Upon Exercise Of Class Of Warrant Or Right	600,000	'

Note_2_Liquidity_Details

Note 2 - Liquidity (Details) (USD $)	3 Months Ended		9 Months Ended
Note 2 - Liquidity (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Note 2 - Liquidity (Details) [Line Items]	'	'	'	'
Net Income (Loss) Attributable to Parent	$127,918	$129,229	$743,944	($30,490)
Net Cash Provided by (Used in) Operating Activities	'	'	-1,671,623	-1,899,065
Revolving Credit Facility [Member] \| Diamedix Corporation [Member] \| City National Bank of Florida [Member]	'	'	'	'
Note 2 - Liquidity (Details) [Line Items]	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$2,000,000	'	$2,000,000	'

Note_3_StockBased_Compensation2

Note 3 - Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended		9 Months Ended	0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jun. 06, 2014	Jun. 01, 2014	Sep. 30, 2014	22-May-14	Jun. 06, 2014	Jun. 01, 2014
					Employee Stock Option [Member]	Employee Stock Option [Member]	Board of Directors and Former Executive Officer [Member]	Director [Member]	Executive Officer [Member]	Executive Officer [Member]
					Executive Officer [Member]	Executive Officer [Member]
Note 3 - Stock-Based Compensation (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'4 years	'	'3 years	'1 year	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	'	'	350,000	'	'	'	350,000	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)	'	'	$0.89	'	'	'	$0.89	'	'	'
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	'	'	'	'	'	'	$310,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	'	'	65,000	'	'	'	'	30,000	10,000	25,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	'	'	$1,770,000	'	'	'	'	$1.76	$1.63	$1.76
Allocated Share-based Compensation Expense	$4,000	$134,000	$51,000	$134,000	'	'	'	'	'	'

Note_3_StockBased_Compensation3

Note 3 - Stock-Based Compensation (Details) - Stock Option Activity (USD $)	9 Months Ended
	Sep. 30, 2014
Stock Option Activity [Abstract]	'
Balance as of December 31, 2013	1,170,870
Balance as of December 31, 2013	$1.33
Stock options granted	65,000
Stock options granted	$1,770,000
Stock options exercised	-350,000
Stock options exercised	$0.89
Balance as of September 30, 2014	885,870
Balance as of September 30, 2014	$1.54

Note_5_Accounts_Receivable_and2

Note 5 - Accounts Receivable and Allowance for Doubtful Accounts (Details) - Accounts Receivable, Net (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accounts Receivable, Net [Abstract]	'	'
Accounts receivable	$7,515,114	$6,964,357
Less: allowance for doubtful accounts	-1,129,797	-1,417,642
Accounts receivable, net	$6,385,317	$5,546,715

Note_6_Inventories_Net_Details

Note 6 - Inventories, Net (Details) - Components of Inventory (USD $)	Sep. 30, 2014	Dec. 31, 2013
Components of Inventory [Abstract]	'	'
Raw materials	$1,068,047	$3,123,380
Work-in-process	748,664	624,454
Finished goods	5,442,384	2,746,339
Total inventories, net	$7,259,095	$6,494,173

Note_7_Income_Loss_Per_Share_D

Note 7 - Income (Loss) Per Share (Details)	3 Months Ended		9 Months Ended
Note 7 - Income (Loss) Per Share (Details)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	150,000	12,674,573	150,000	15,854,204

Note_8_Income_Taxes_Details

Note 8 - Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
Note 8 - Income Taxes (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 01, 2010
Note 8 - Income Taxes (Details) [Line Items]	'	'	'	'	'	'
Current Federal Tax Expense (Benefit)	'	'	$0	$0	'	'
Income (Loss) from Continuing Operations before Income Taxes, Domestic	'	'	-709,000	-291,000	'	'
Deferred Tax Liabilities, Net	658,030	'	658,030	'	576,160	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	'	'	'	'	18,110,000	'
Business Acquisition, Percentage of Voting Interests Acquired	'	'	'	'	'	72.40%
Operating Loss Carryforward, Limitations on Use, Amount	'	'	827,000	'	'	'
Income Tax Expense (Benefit)	29,133	27,294	88,176	79,988	'	'
Deferred Federal Income Tax Expense (Benefit)	17,197	17,277	52,000	46,000	'	'
Current Income Tax Expense (Benefit)	'	'	0	0	'	'
Domestic Tax Authority [Member]	'	'	'	'	'	'
Note 8 - Income Taxes (Details) [Line Items]	'	'	'	'	'	'
Deferred Tax Assets, Net of Valuation Allowance	0	'	0	'	0	'
Foreign Tax Authority [Member]	'	'	'	'	'	'
Note 8 - Income Taxes (Details) [Line Items]	'	'	'	'	'	'
Deferred Tax Assets, Net of Valuation Allowance	$0	'	$0	'	'	'

Note_8_Income_Taxes_Details_Pr

Note 8 - Income Taxes (Details) - Provision for Income Taxes (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Current:	'	'	'	'
Foreign	($11,936)	($10,017)	($36,585)	($33,688)
Deferred:	'	'	'	'
Domestic	-17,197	-17,277	-52,000	-46,000
Total	($29,133)	($27,294)	($88,176)	($79,988)

Note_9_Concentration_of_Credit1

Note 9 - Concentration of Credit Risk (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
			Hospitals and Laboratories [Member]	Hospitals and Laboratories [Member]	Sales Revenue, Net [Member]	Sales Revenue, Net [Member]	Hospitals and Laboratories [Member]	Hospitals and Laboratories [Member]	Delta Biologicals [Member]	Delta Biologicals [Member]
			Accounts Receivable [Member]	Accounts Receivable [Member]	Geographic Concentration Risk [Member]	Geographic Concentration Risk [Member]	Delta Biologicals [Member]	Delta Biologicals [Member]	ITALY	ITALY
			Geographic Concentration Risk [Member]	Geographic Concentration Risk [Member]	Delta Biologicals [Member]	Delta Biologicals [Member]	ITALY	ITALY
			ITALY	ITALY	ITALY	ITALY
Note 9 - Concentration of Credit Risk (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Accounts Receivable, Gross, Current	$7,515,114	$6,964,357	'	'	'	'	'	'	$4,007,000	$4,647,000
Amount Due From Hospitals and Laboratories in Total Net Accounts	'	'	'	'	'	'	1,306,000	1,700,000	'	'
Concentration Risk, Percentage	'	'	20.00%	31.00%	21.00%	17.00%	'	'	'	'
Revenues	'	'	'	'	$4,292,000	$3,505,000	'	'	'	'

Note_10_Segment_Information_De

Note 10 - Segment Information (Details) - Segment Reporting Information (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	$6,469,488	$6,940,713	$20,381,257	$20,538,079	'
Income (loss) from operations	351,066	78,541	1,154,282	229,924	'
Assets	26,402,316	25,644,211	26,402,316	25,644,211	25,874,466
Goodwill	3,494,619	3,494,619	3,494,619	3,494,619	3,494,619
External Net Sales [Member] \| Reportable Geographical Components [Member] \| Domestic [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	5,231,530	5,711,672	16,114,540	17,049,329	'
External Net Sales [Member] \| Reportable Geographical Components [Member] \| Europe [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	1,237,958	1,229,041	4,266,717	3,488,750	'
External Net Sales [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	6,469,488	6,940,713	20,381,257	20,538,079	'
Intercompany Sales [Member] \| Reportable Geographical Components [Member] \| Domestic [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	80,433	60,167	290,559	296,457	'
Intercompany Sales [Member] \| Reportable Geographical Components [Member] \| Europe [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	8,721	3,075	25,054	16,529	'
Intercompany Sales [Member] \| Geography Eliminations [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	-89,154	-63,242	-315,613	-312,986	'
Reportable Geographical Components [Member] \| Domestic [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	5,311,963	5,771,839	16,405,099	17,345,786	'
Income (loss) from operations	375,555	219,149	1,008,084	721,528	'
Assets	41,177,570	40,493,671	41,177,570	40,493,671	'
Goodwill	3,494,619	3,494,619	3,494,619	3,494,619	'
Reportable Geographical Components [Member] \| Europe [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	1,246,679	1,232,116	4,291,771	3,505,279	'
Income (loss) from operations	-24,489	-140,608	146,198	-491,604	'
Assets	5,684,971	5,610,765	5,684,971	5,610,765	'
Geography Eliminations [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenue	-89,154	-63,242	-315,613	-312,986	'
Assets	($20,460,225)	($20,460,225)	($20,460,225)	($20,460,225)	'

Note_12_Related_Party_Transact1

Note 12 - Related Party Transactions (Details)

3 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Oct. 03, 2012

Apr. 16, 2012

Jun. 30, 2011

Sep. 30, 2014

Sep. 30, 2013

Apr. 08, 2011

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2014

Dec. 31, 2011

Sep. 30, 2014

Dec. 31, 2012

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

USD ($)

Stock Purchase Agreement [Member]

Transasia Bio-Medicals Ltd. [Member]

ERBA Diagnostics Mannheim [Member]

ERBA Diagnostics Mannheim and Transasia [Member]

ERBA Diagnostics France [Member]

Director [Member]

ERBA Diagnostics Mannheim [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Immunovision Inc. [Member]

USD ($)

The Second Closing [Member]

The Final Closing [Member]

USD ($)

Note 12 - Related Party Transactions (Details) [Line Items]

Revenue from Related Parties

$1,280,000

$24,000

$1,874,000

$70,000

Related Party Transaction, Amounts of Transaction

186,000

754,700

6,000

Related Party Transaction Due To Related Party

133,000

799,000

621,700

Research and Development Arrangement, Contract to Perform for Others, Compensation Earned

350,000

200,000

148,000

387,000

286,000

462,500

Accounts Receivable, Related Parties, Current

1,898,000

1,835,000

Research and Development Monthly Installments (in Euro)

50,000

Common Stock, Capital Shares Reserved for Future Issuance (in Shares)

8,666,667

4,666,666

20,000,000

Common Stock, Capital Shares Reserved for Future Issuance, Value

6,500,000

3,500,000

15,000,000

Share Price (in Dollars per share)

$0.75

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

14,733,334

20,000,000

Minimum Percentage of Approval by Shareholders

0.6666

Stock Issued During Period, Value, New Issues

5,000,000

Stock Issued During Period, Shares, New Issues (in Shares)

8,666,667

6,666,667

Payments of Stock Issuance Costs

399,700

Proceeds from Issuance of Common Stock

6,500,000

4,600,300

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.75

Proceeds from Warrant Exercises

450,000

Stock Shares Issued Upon Exercise Of Class Of Warrant Or Right (in Shares)

600,000

Class of Warrant or Right, Outstanding (in Shares)

19,400,000

Consulting Agreement Consideration Per Month

2,000

Royalty Fee Annual Minimum

10,000

Annual License Fees

$2,500

$5,000

Note_13_Revolving_Line_of_Cred1

Note 13 - Revolving Line of Credit (Details) (Revolving Credit Facility [Member], Citibank, N.A. [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
	London Interbank Offered Rate (LIBOR) [Member]	Minimum [Member]	Sep. 30, 2014	Dec. 31, 2013
Note 13 - Revolving Line of Credit (Details) [Line Items]	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	$2,000,000	'
Debt Instrument, Basis Spread on Variable Rate	1.75%	'	'	'
Line of Credit Facility, Interest Rate at Period End	'	'	1.90%	'
Minimum Net Worth Required for Compliance	'	'	8,500,000	'
Leverage Ratio	'	2	'	'
Long-term Line of Credit	'	'	$1,940,000	$1,905,000